531015 — Venmax Drugs and Pharmaceuticals Balance Sheet
0.000.00%
- IN₹131.18m
- IN₹106.85m
- IN₹8.07m
Annual balance sheet for Venmax Drugs and Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.753 | 0.003 | 0.003 | 0.025 | 24.8 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.362 | 0.364 | 0.364 | 0 | 25.6 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 2.17 | 1.33 | 1.38 | 0.156 | 51.3 |
Net Property, Plant And Equipment | 0.621 | 0.556 | 0.5 | 0.45 | 0.405 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 3.08 | 2.14 | 2.11 | 0.814 | 51.7 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 30.9 | 11.5 | 9.21 | 7.27 | 7.57 |
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 30.9 | 11.5 | 9.26 | 7.32 | 7.58 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -27.9 | -9.4 | -7.14 | -6.5 | 44.1 |
Total Liabilities & Shareholders' Equity | 3.08 | 2.14 | 2.11 | 0.814 | 51.7 |
Total Common Shares Outstanding |